• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » J&J’s DePuy can’t delay 3rd bellwether in Pinnacle hip MDL

J&J’s DePuy can’t delay 3rd bellwether in Pinnacle hip MDL

July 6, 2016 By Brad Perriello

DePuy Orthopaedics Pinnacle implantA Johnson & Johnson (NYSE:JNJ) subsidiary can’t delay an upcoming bellwether trial in the multi-district litigation over its Pinnacle metal-on-metal hip implant, a federal judge in Texas ruled yesterday.

DePuy Orthopaedics asked Judge Ed Kinkeade of the U.S. District Court for Northern Texas for a stay of the 3rd bellwether trial in the MDL, which involves more than 8,000 cases. The company also asked a federal appeals court to hit the pause button to give it enough time to appeal a $500 million jury verdict in the 2nd bellwether. DePuy wanted Kinkeade to pause the 3rd bellwether while the the U.S. Court of Appeals for the 5th Circuit considers its petition for a writ of mandamus.

In March, a Texas federal jury slapped DePuy Orthopaedics with a $500 million judgment in favor of a quintet of plaintiffs who blamed the Pinnacle implant for their injuries. After a 2-month trial, jurors found that the Ultamet metal-on-metal version of the Pinnacle hips were defectively designed and that DePuy failed to warn patients about the risks, awarding $130 million in total compensatory damages and $360 million in punitive damages. DePuy won the 1st bellwether trial in the MDL, in October 2014.

DePuy argued that the next bellwether involving 7 plaintiffs slated for trial Sept. 6 should be delayed, accusing Kinkeade of abusing the bellwether process and allowing “the injection of all manner of irrelevant and highly inflammatory evidence” in the 2nd bellwether.

In declining to institute a stay, Kinkeade ruled that DePuy ignored his warnings that introducing evidence of “good character, product safety, success of their products abroad, and positive scientific literature” would allow the plaintiffs to refute the claims with contrary evidence.

“[T]he Court warned defendants on numerous occasions that if they presented certain defenses, plaintiffs would be permitted to introduce evidence to refute it. Defendants, not plaintiffs, opened the door to the evidence defendants now claim was error to admit. It will be defendants’ choices that govern whether this evidence is admitted in future trials,” Kinkeade wrote.

“Defendants are asking for a stay that is inconsistent with the agreed-upon bellwether trial plan and is unjustified based on a balancing of interests. This MDL has already been pending for 5 years. The representative plaintiffs in the consolidated bellwether trial this year averaged 68 years old. The court believes that a stay would unduly prejudice plaintiffs and delay resolution of this matter to the detriment of all parties. Exercising its judgment, weighing the competing interests, and maintaining an even balance, the court finds that the bellwether trials should proceed as originally agreed,” he wrote.

Filed Under: Legal News, Orthopedics, Product Liability Tagged With: depuysynthes, Johnson and Johnson

More recent news

  • Breaking: Sequel to launch twiist automated insulin delivery system next month
  • Dexcom shares U.S. report on CGM benefits for type 2 diabetes
  • Data backs Medtronic MiniMed 780G for type 2, children as company seeks expanded indications
  • Endogenex data supports type 2 diabetes procedure
  • Ambu wins FDA clearance for first single-use cysto-nephroscope

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy